Table 4.
Cancer risk following first lymphoid malignancy by latency period (< 6 months or >6 months after lymphoid malignancy).
| 6 months or less after first primary lymphoid malignancy diagnosis | More than 6 months after first primary lymphoid malignancy diagnosis | ||||||
|---|---|---|---|---|---|---|---|
| Cancers | Number of cancers (N) | Number with first primary lymphoid malignancies N (row %) | aHR (95% CI) Model 1a | aHR (95% CI) Model 2a | No. with first primary lymphoid malignancies [N (row %)] | aHR (95% CI) Model 1a | aHR (95% CI) Model 2a |
| Any nonlymphoid malignancy | 18 944 | 84 (0.4) | 7.3 (5.9–9.1) | 2.7 (2.2–3.4) | 142 (0.7) | 1.8 (1.6–2.2) | 1.5 (1.3–1.8) |
| Oral cavity | 511 | 0 (0) | … | … | 7 (1.4) | 2.9 (1.4–6.2) | 2.5 (1.2–5.2) |
| Colon | 601 | 4 (0.7) | 11.0 (4.1–29.5) | 5.4 (2.0–14.6) | 3 (0.5) | 1.2 (0.4–3.6) | 1.1 (0.4–3.5) |
| Rectum | 549 | 2 (0.4) | … | … | 8 (1.5) | 3.3 (1.6–6.6) | 2.8 (1.4–5.6) |
| Anus | 1744 | 9 (0.5) | 7.9 (4.1–15.3) | 3.4 (1.8–6.5) | 23 (1.3) | 3.0 (2.0–4.5) | 2.4 (1.6–3.5) |
| Liver | 1377 | 1 (<0.1) | … | … | 12 (0.9) | 2.1 (1.2–3.8) | 2.0 (1.1 −3.5) |
| Lung | 3111 | 10 (0.3) | 5.5 (3.0–10.2) | 2.1 (1.2–4.0) | 14 (0.5) | 1.1 (0.6–1.8) | 0.9 (0.6–1.6) |
| Kaposi sarcoma | 2379 | 36 (1.5) | 24.4 (17.5–33.9) | 4.4 (3.2–6.1) | 8 (0.3) | 1.0 (0.5–2.0) | 0.6 (0.3–1.2) |
| Female breast | 873 | 1 (0.1) | … | … | 4 (0.5) | 1.6 (0.6–4.2) | 1.6 (0.6–4.1) |
| Prostate | 1803 | 1 (<0.1) | … | … | 6 (0.3) | 0.6 (0.3–1.4) | 0.6 (0.3–1.4) |
| Kidney | 441 | 2 (0.5) | … | … | 3 (0.7) | 1.6 (0.5–5.1) | 1.6 (0.5–4.9) |
| Myeloid malignanciesb | 447 | 1 (0.2) | … | … | 18 (4.0) | 10.6 (6.6–17.0) | 9.1 (5.6–14.6) |
| Miscellaneousc | 1237 | 5 (0.4) | 6.8 (2.8–16.4) | 2.5 (1.1 −6.1) | 14 (1.1) | 2.8 (1.7–4.8) | 2.4 (1.4–4.1) |
Highlighted aHRs and 95% CIs indicate estimates that were statistically significant with P < 0.05. (…) Hazard ratios were suppressed for comparisons when there were less than two nonlymphoid cancers with prior lymphoid malignancies. Model 2: models adjusted for sex/risk group, race/ethnicity, calendar year of cohort entry, and prior AIDS diagnosis and time since HIV diagnosis as time-varying covariates. Models 1 and 2 had age as the time scale. aHR, adjusted hazard ratio; CI, confidence interval.
Model 1: Models adjusted for sex/risk group, race/ethnicity, and calendar year of cohort entry.
Myeloid malignancies include myelodysplasia, myeloproliferative neoplasms, and other myeloid malignancies.
Miscellaneous cancers include cancers of the following sites: salivary glands (N = 32), other oral cavity/pharynx (N = 85), small intestine (N = 70), other gastrointestinal tract (N = 33), other respiratory tract (N = 49), bone and cartilage (N = 77), male breast (N = 32), other female genital tract (N = 88), other male genital tract (N = 25), eye and orbit (N = 39), other urinary tract (N = 21), other endocrine glands (N = 26), and unknown primary site (N = 660).